Skipping surgery for triple-negative breast cancer with no sign of disease
Part of Cancer, Skin clinical trials.
This trial aims to see if it is safe to skip surgery for women with triple-negative breast cancer who have no remaining cancer after chemotherapy and immunotherapy. If you qualify, you would avoid surgery but still receive close monitoring to ensure the cancer doesn't come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with 'triple-negative' breast cancer (a type that doesn't respond to hormone therapy or HER2-targeted drugs).
- Your tumor was between 2 and 5 cm when first found, and it had not spread to your lymph nodes or other parts of your body.
- You finished the full standard chemotherapy plus immunotherapy treatment (called the KEYNOTE-522 regimen).
- After that treatment, a breast MRI and a needle biopsy showed no remaining cancer in the breast.
- Doctors had planned that you could undergo lumpectomy (removing just the lump) if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if a breast biopsy can confirm that chemo has destroyed all cancer cells, so you might avoid surgery altogether. It's for people with aggressive breast cancer types who responded well to chemotherapy.
This trial tests if it's safe to skip a sentinel lymph node biopsy (a procedure to check if cancer has spread to the lymph nodes under your arm) when the breast tumor has completely disappeared after chemotherapy. If the trial finds it's safe, you could avoid this extra surgery and its side effects.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests whether women with HER2-positive or triple-negative breast cancer who had a complete response to chemotherapy can safely skip radiation or additional surgery. If you had a complete tumor response after chemo and had breast-conserving surgery, you may be eligible.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.